News Medical on MSN9 小时
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
Medpage Today on MSN2 天
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...
News Medical on MSN4 天
GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Medpage Today on MSN3 天
How Often Do Doctors Use New Weight-Loss Drugs in Kids?
As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...
pulmonologyadvisor3 天
GLP-1 Drug Shortages: How Do They Affect Patients With Diabetes?
GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
Tyler Morning Telegraph6 天
Texas Has the 10th Lowest Rate of GLP-1 Use in the Nation
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The Laconia Daily Sun6 天
New Hampshire Residents Are Using GLP-1s at a Slightly Below Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally developed for managing type 2 diabetes—have rapidly increased in popularity.
Pennsylvania Residents Are Using GLP-1s at the 10th Highest Rate in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The Grand Junction Daily Sentinel6 天
Colorado Residents Are Using GLP-1s at the 3rd Lowest Rate in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The Exponent6 天
Montana Has the 14th Lowest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
thecutoffnews6 天
Alabama Has the 3rd Highest Rate of GLP-1 Use in the Nation
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...